Floatz logo

txa127

Acute Myelogenous Leukemia

Tarix PharmaceuticalsPhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

26 Active assets in the Acute Myelogenous Leukemia cohort.

Asset / SponsorPhaseRating
Posaconazole
AstraZeneca
Phase 4BBB
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs
Fred Hutchinson Cancer Center
Phase 2/3BB
Vesanoid
The First Affiliated Hospital of Soochow University
Phase 3BB
Valproic Acid
University of Bergen
Phase 2BB
MERCAPTOPURINE ANHYDROUS
University Hospital, Antwerp
Phase 3BB

View all 50 →

Same molecule, other indications

txa127 is also rated in:

Double Cord Blood TransplantDormant
CC
Indicative ·
43 / 100
View asset →
Chronic Myelocytic LeukemiaDormant
CC
Indicative ·
43 / 100
View asset →
Non Hodgkins LymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →